ERBB2 and cholangiocarcinoma: Only one patient with BTC (EGFR amplified, KRASWT cholangiocarcinoma) achieved an unconfirmed PR, and eight patients (three KRASWT BTC, of whom one was HER2 amplified, one KRASWT PDA with HER3 protein overexpression but not HER3 amplified by NGS, three KRASMUT PDA, and one KRASMUT BTC) had SD.